Evidence map›Paper›PMID 40625832›Full record

Observational studyFrontiers in cellular and infection microbiology2025

Clinical evaluation of a novel

Wen-Juan Wei, Bang Sun He, Bin Lv, Bin Yang, Yong Xie, Zhen Yu Zhang

Registry-linked trialAbstract readEvaluation StudyMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05410652 (A Multicenter Clinical Study of Helicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05410652 completednot on this map

A Multicenter Clinical Study of Helicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method)

TypeobservationalSponsorNanjing First Hospital, Nanjing Medical UniversityRan2022 to 2023Enrolled1,176ConditionsHelicobacter Pylori Infection, Helicobacter Pylori gyrA Levofloxacin Resistance Mutation, Fecal Drug Resistance Gene Detection, Helicobacter Pylori Infection, Susceptibility toArmsDetection of fecal samples with diagnostic kit, Sanger Sequencing group, Bacterial culture and drug sensitivity test of gastric mucosa samples
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wen-Juan WeiDepartment of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Bang Sun HeDepartment of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Bin LvDepartment of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Bin YangDepartment of Gastroenterology, Jiangsu Taizhou People's Hospital, Taizhou, Jiangsu, China.
Yong XieJiangxi Clinical Research Center for Gastroenterology, First Affiliated Hospital of Nanchang University, Department of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Nanchang, China.
Zhen Yu ZhangDepartment of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: A total of 1,176 participants from four clinical centers in China were enrolled between August 2022 and October 2023. Phenotypic resistance was assessed on Results: There was a high level of consistency between phenotypic testing and novel diagnostic kit. The PPA, NPA, and OPA of the fecal diagnostic kit for detecting clarithromycin susceptibility were 92.97% (CI: 90.6%-95.3%), 87.89% (CI: 85.0%-90.8%), and 90.36% (CI: 88.5%-92.3%), respectively. And likewise, the PPA, NPA, and OPA in diagnosing Conclusions: The fecal diagnostic kit provides a rapid, non-invasive, and reliable method to predict clarithromycin and fluoroquinolone resistance, supporting personalized therapy. Clinical Trial Registration: ClinicalTrials.gov, identifier NCT05410652.

Indexed as

Anti-Bacterial AgentsClarithromycinDrug Resistance, BacterialFecesFluoroquinolonesHelicobacter InfectionsHelicobacter pyloriMolecular Diagnostic TechniquesMultiplex Polymerase Chain ReactionAdultAgedChinaDNA GyraseFemaleHumansMaleAnti-Bacterial AgentsClarithromycinDNA GyraseFluoroquinolonesRNA, Ribosomal, 23Sclarithromycin resistancefecal diagnostic kitfluoroquinolones resistanceHelicobacter pylorimolecular diagnosis

Identifiers

PMID40625832
PMCPMC12230099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.